is hims glp 1 safe & @Hers sees strong early results from its GLP-1 weight loss program. New internal data shows users lost an average of 20.9 pounds in six months, with high adherence and low Hims & Hers Health (HIMS)

Dual GLP-1/GIP agonists are in preclinical evaluation for synergistic neuroprotection

doi: 10.1007/s11154-022-09735-8

NYSE: LLY launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023

Understanding whether this represents a direct medication effect, an indirect consequence of therapy, or coincidental occurrence is essential for appropriate clinical management and informed decision-making

For those just starting a tirzepatide protocol, the tirzepatide reconstitution guide and injection site guidance ensure proper preparation and administration

As a result, brands in categories from health supplements to skin care are thinking through what this change in behavior could mean for their companies